Nautilus set to go public in reverse merger with Perceptive SPAC, aims to test proteomics platform with big-name backers

With the backing of Paul Allen and Jeff Bezos, among others, Nautilus Biotechnology is setting sail for Nasdaq, inking a deal with one of Perceptive’s blank-check companies to unlock the mysteries of the human proteome.

The Seattle-based biotech will reverse merge with Arya Sciences Acquisition Corp III, which penciled in a $143.7 million IPO raise back in late-July, Nautilus said Monday. In August, the SPAC priced 13,000,000 shares at $10 apiece.